CVS Stock Returned $24B In Cash: Why Did It Still Lag The Market

The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here's the accounting of what that trade-off actually delivered.

What if a company handed you checks equal to 20% of its entire value, but your stock still trailed the market? For owners of CVS Health (CVS), that's not a hypothetical. Over the last five years, the company returned a large $24.4 billion to shareholders through dividends and buybacks. The paradox is that while the cash flowed, the stock lagged. The question for any owner is whether holding on was worth it, and if it makes sense from here.

How Did a Company Worth $121 Billion Generate So Much Cash?

The money machine at CVS is vast, spanning insurance, pharmacy benefits, and retail stores. The company's free cash flow over the trailing twelve months was $11.76 billion. On its latest earnings call management raised its full-year 2026 outlook for cash flow from operations to at least $11.50 billion, up from $9.50 billion, funding a capital return program more than four times the $5.6 billion the median S&P 500 company paid out over the same five years, though as a share of market value the gap is narrower: 20% for CVS against about 17% for the median. That $24.4 billion five-year total came in two forms: $15.9 billion in steady dividend checks and another $8.5 billion in share repurchases.

This financial engine is humming. The company boosted its adjusted earnings per share guidance to a range of $7.90 to $8.10, citing strong performance as each of its operating segments grew earnings.

The Payouts Cushioned a Long Stretch of Underperformance

Here is the hard math for shareholders. Over the last five years, holding CVS stock produced a total return of +29%, dividends included. Over that same period, an investment in an exchange-traded fund that tracks the S&P 500 would have returned +80%. The cash from CVS was real, but it wasn't enough to close that gap. A recent analysis asks whether CVS stock has truly left its peers behind, a question investors have been grappling with.

The market's hesitation isn't random. A large payout can signal discipline, but it can also suggest a business is running out of high-return ways to reinvest its own cash. The primary concern centers on the company's large Health Services segment, which includes the Caremark pharmacy benefit manager. Management has been transparent about future challenges, stating, "we believe we will see membership declines in Caremark next year." They also flagged that market dynamics in its 340B business are expected to "result in a headwind in 2027." This is the business risk that helps explain the stock's long-term lag.

The Test Is Whether Aetna's Strength Can Offset Caremark's Headwinds

For the checks to keep coming, the enterprise as a whole has to overcome the specific weakness in its pharmacy services arm. The bull case rests on the Aetna insurance division, where management noted it has "delivered more than $2 billion of year-over-year improvement in adjusted operating income." That strength, combined with momentum in its retail pharmacy business, provides a powerful offset to the Caremark pressures.

A key metric for investors to watch is whether this balance holds. Management has already given a preliminary look, saying a 2027 adjusted EPS outlook of at least $8.44, consistent with current consensus, appears reasonable at this juncture. Hitting that target, about 13% growth off the $7.46 adjusted baseline management cites, despite the known pressures in a core division, is the ultimate test of whether the CVS cash machine can keep rewarding its owners.

To see where this record sits against the market's other great cash returners, our Buybacks & Dividends ranking holds the full league table.

The Checks Are Real. So Is The Concentration Question

Cash returned to shareholders is the most tangible reward in investing, and it can still be outweighed by a single stock's decline if that stock is most of what you own.

The Trefis High Quality (HQ) Portfolio balances the ledger: roughly 30 quality names across sectors, selected on the fundamentals that make payouts sustainable, sized and re-balanced with discipline. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Collect the checks; spread the risk.